These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2521895)

  • 1. Increase in kynurenic acid in Huntington's disease motor cortex.
    Connick JH; Carlà V; Moroni F; Stone TW
    J Neurochem; 1989 Mar; 52(3):985-7. PubMed ID: 2521895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.
    Jauch D; Urbańska EM; Guidetti P; Bird ED; Vonsattel JP; Whetsell WO; Schwarcz R
    J Neurol Sci; 1995 May; 130(1):39-47. PubMed ID: 7650530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
    Beal MF; Matson WR; Storey E; Milbury P; Ryan EA; Ogawa T; Bird ED
    J Neurol Sci; 1992 Mar; 108(1):80-7. PubMed ID: 1385624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
    Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
    Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE; Landis DM; Zalneraitis EL
    Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
    Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED
    J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
    Dure LS; Young AB; Penney JB
    Ann Neurol; 1991 Dec; 30(6):785-93. PubMed ID: 1665055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

  • 11. Decreased proline endopeptidase activity in the basal ganglia in Huntington's disease.
    Pittaway KM; Reynolds GP; Emson PC
    J Neurochem; 1984 Sep; 43(3):878-80. PubMed ID: 6235325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pallidal GABA and chorea in Huntington's disease.
    Pearson SJ; Heathfield KW; Reynolds GP
    J Neural Transm Gen Sect; 1990; 81(3):241-6. PubMed ID: 2144428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects.
    Urquhart N; Perry TL; Hansen S; Kennedy J
    J Neurochem; 1975 May; 24(5):1071-5. PubMed ID: 124764
    [No Abstract]   [Full Text] [Related]  

  • 15. Aggregate distribution in frontal and motor cortex in Huntington's disease brain.
    van Roon-Mom WM; Hogg VM; Tippett LJ; Faull RL
    Neuroreport; 2006 Apr; 17(6):667-70. PubMed ID: 16603932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis.
    Sapp E; Ge P; Aizawa H; Bird E; Penney J; Young AB; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Jan; 64(2):397-404. PubMed ID: 7535402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
    Ellison DW; Beal MF; Mazurek MF; Malloy JR; Bird ED; Martin JB
    Brain; 1987 Dec; 110 ( Pt 6)():1657-73. PubMed ID: 2892568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
    Marshall PE; Landis DM
    Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
    Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
    Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.